04 April 2019 | News
The partnership reflects the expanding synergism of Indo-Israel medical collaboration
Israel based Ocular Discovery and All India Institute of Medical Sciences (AIIMS) in New Delhi, have announced the launch of a novel research partnership investigating the mechanism of action of DCGI (Drug Controller General of India) approved Dipyridamole, for optimized delivery and therapeutic treatment of various Ocular Surface Disorders (OSD).
The research collaboration led by Dr. T Velpandian, AIIMS and Moshe Rogosnitzky, Ocular Discovery, seeks to illuminate the drug's mechanism of action and effectiveness in the treatment of widespread Ocular Surface Disorders in order to advance delivery, optimize dosage, and substantiate its use as a viable treatment option.
Globally prescribed Dipyridamole, used for the treatment of cardiovascular conditions for over 50 years; is already approved and available in Israel for the relief of various ocular conditions and disorders. The drug has shown marked symptomatic benefit in patients with pterygium and related dry eye symptoms, as well as offers accessible and efficient delivery of the medication.